Albert Farrugia, University of Western Australia
Blood safety and availability – current and emerging issues. Presentation

William Murphy, Irish Blood Transfusion Service, Ireland
Impact of MSM donor deferrals on safety and supply. Presentation

Marijke van den Berg, University Hospital of Utrecht, Netherlands
EMA guidelines on transparency for clinical trials. Presentation

Albert Farrugia, University of Western Australia
Barriers to access in the developing world. Presentation

Kathleen Rowe, Blood Centers of America (BCA), USA
The changing economics of blood collection. Presentation

Brian O’Mahony, Irish Haemophilia Society, Ireland
Tender & procurement – challenges and opportunities. Presentation

Assad Haffar, World Federation of Hemophilia (WFH)
Expansion of the WFH Humanitarian Aid program. Presentation

Alfonso Iorio, McMaster University, Canada
How to measure progress in the provision of care for hemophilia. Presentation

Mark Brooker, World Federation of Hemophilia (WFH)
Inclusion of DDAVP on WHO Essential Medicines List and implications for access. Presentation

Magdy El Ekiaby, Shabrawishi Hospital, Egypt Outcomes of low-dose prophylaxis in children. Presentation

Anneliese Hilger, Paul-Ehrlich-Institut, Germany
Report on the EMA workshop on hemophilia registries. Presentation

Mike Soucie, Centers for Disease Control and Prevention (CDC), USA
Surveillance for inhibitors in the US. Presentation

Glenn Pierce, Board of Directors, World Federation of Hemophilia (WFH)
Report on FDA inhibitor workshop. Presentation

Thomas R. Kreil, Baxter BioScience
New Technologies for Virus Testing: Where Donor Screening is going. Presentation

J. Michael Soucie, Centers for Disease Control and Prevention
Transmission of B19 and hepatitis E by plasma products. Presentation

Johannes Bluemel, Paul-Ehrlich-Institut
Viral inactivation on non-lipid viruses such as parvovirus B19 and hepatitis E. Presentation

Magdy El Ekiaby, Shabrawichi Hospital
Pessimistic on plasma. Presentation

Pierre-François Falcou, LFB Biomedicaments
Optimistic on plasma. Presentation

Marilyn Manco-Johnson, The University of Colorado Hemophilia & Thrombosis Center
Is the annual bleed rate enough? The micropathology of joints. Presentation

Albert Farrugia, Plasma Protein Therapeutics Association
Economic considerations – pricing, sustainability, access, increased supply? Presentation

Mark W. Skinner, WFH USA
Patient perspective. Presentation

Judie Leach Bennett, Candian Blood Services
Risk-based decision making for blood safety: An international consensus conference – report and future steps. Presentation

Mark W. Skinner, World Federation of Hemophilia
MSM donor deferral. Presentation

Nathan Schaefer, MSSA, Gay Men’s Health Crisis
Advocacy to revise blood donation policies for MSM. Presentation

Steven Kleinman, Blood Systems Research Institute
HIV data from a multicenter efficacy study of HIV, HCV, and HBV blood screening scenarios. Presentation

Albert Farrugia, Plasma Protein Therapeutics Association
Hemophilia and health technology assessment. Presentation

J. Michael Soucie, Centers for Disease Control and Prevention
Update on studies of inhibitors. Presentation

Carol K. Kasper, University of Southern California
How do we define a (clinically-relevant) inhibitor? Presentation

Corien Eckhardt, INSIGHT investigators
Inhibitor development in mild/moderate hemophilia A. Presentation

Elena Santagostino, Milan, Italy
SIPPET and EUHASS studies. Presentation

Jerry S. Powell, Hemostasis and Thrombosis Center, University of California Davis
New products for treatment of hemophilia ‒ changing options and clinical trial design. Presentation

Donna Di Michele, project group of the FVIII/IX subcommittee
Clinical trial design for hemophilia. Presentation

Alok Srivastava, on behalf of the FVIII/IX sub-committee SSC-ISTH project group
Potency assignment of clotting factor concentrates. Presentation